Bank of New York Mellon’s Arcus Biosciences RCUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $16.7M | Buy |
543,009
+31,843
| +6% | +$787K | ﹤0.01% | 1732 |
|
|
2026
Q1 | $11M | Buy |
511,166
+6,704
| +1% | +$145K | ﹤0.01% | 1887 |
|
|
2025
Q4 | $12M | Buy |
504,462
+34,252
| +7% | +$699K | ﹤0.01% | 1826 |
|
|
2025
Q3 | $6.39M | Sell |
470,210
-13,843
| -3% | -$144K | ﹤0.01% | 2183 |
|
|
2025
Q2 | $3.94M | Buy |
484,053
+82,483
| +21% | +$705K | ﹤0.01% | 2405 |
|
|
2025
Q1 | $3.15M | Buy |
401,570
+19,955
| +5% | +$231K | ﹤0.01% | 2449 |
|
|
2024
Q4 | $5.68M | Buy |
381,615
+30,290
| +9% | +$495K | ﹤0.01% | 2224 |
|
|
2024
Q3 | $5.37M | Sell |
351,325
-44,541
| -11% | -$702K | ﹤0.01% | 2261 |
|
|
2024
Q2 | $6.03M | Sell |
395,866
-4,303
| -1% | -$69.5K | ﹤0.01% | 2238 |
|
|
2024
Q1 | $7.56M | Sell |
400,169
-17,585
| -4% | -$304K | ﹤0.01% | 2111 |
|
|
2023
Q4 | $7.98M | Sell |
417,754
-30,828
| -7% | -$493K | ﹤0.01% | 2111 |
|
|
2023
Q3 | $8.05M | Sell |
448,582
-11,638
| -3% | -$234K | ﹤0.01% | 2063 |
|
|
2023
Q2 | $9.35M | Sell |
460,220
-18,180
| -4% | -$346K | ﹤0.01% | 1981 |
|
|
2023
Q1 | $8.73M | Sell |
478,400
-10,051
| -2% | -$192K | ﹤0.01% | 1997 |
|
|
2022
Q4 | $10.1M | Buy |
488,451
+17,755
| +4% | +$489K | ﹤0.01% | 1937 |
|
|
2022
Q3 | $12.3M | Buy |
470,696
+47,247
| +11% | +$1.25M | ﹤0.01% | 1774 |
|
|
2022
Q2 | $10.7M | Buy |
423,449
+212,614
| +101% | +$5.21M | ﹤0.01% | 1893 |
|
|
2022
Q1 | $6.65M | Sell |
210,835
-29,229
| -12% | -$979K | ﹤0.01% | 2276 |
|
|
2021
Q4 | $9.72M | Buy |
240,064
+19,671
| +9% | +$763K | ﹤0.01% | 2117 |
|
|
2021
Q3 | $7.68M | Buy |
220,393
+16,982
| +8% | +$529K | ﹤0.01% | 2262 |
|
|
2021
Q2 | $5.59M | Buy |
203,411
+33,662
| +20% | +$961K | ﹤0.01% | 2434 |
|
|
2021
Q1 | $4.77M | Sell |
169,749
-12,814
| -7% | -$446K | ﹤0.01% | 2466 |
|
|
2020
Q4 | $4.74M | Buy |
182,563
+18,966
| +12% | +$459K | ﹤0.01% | 2389 |
|
|
2020
Q3 | $2.81M | Sell |
163,597
-5,794
| -3% | -$129K | ﹤0.01% | 2489 |
|
|
2020
Q2 | $4.19M | Buy |
169,391
+20,147
| +13% | +$544K | ﹤0.01% | 2295 |
|
|
2020
Q1 | $2.07M | Buy |
149,244
+24,179
| +19% | +$301K | ﹤0.01% | 2525 |
|
|
2019
Q4 | $1.26M | Buy |
125,065
+141
| +0.1% | +$1.19K | ﹤0.01% | 3112 |
|
|
2019
Q3 | $1.14M | Buy |
124,924
+7,941
| +7% | +$63.8K | ﹤0.01% | 3103 |
|
|
2019
Q2 | $930K | Buy |
116,983
+9,980
| +9% | +$99.9K | ﹤0.01% | 3264 |
|
|
2019
Q1 | $1.34M | Buy |
107,003
+6,766
| +7% | +$73.4K | ﹤0.01% | 2993 |
|
|
2018
Q4 | $1.08M | Buy |
100,237
+79,052
| +373% | +$923K | ﹤0.01% | 3061 |
|
|
2018
Q3 | $295K | Buy |
21,185
+5,138
| +32% | +$65.5K | ﹤0.01% | 3830 |
|
|
2018
Q2 | $196K | Buy |
+16,047
| New | +$252K | ﹤0.01% | 3924 |
|
Other funds holding RCUS
GS
PA
Bank of New York Mellon's RCUS Position: Q2 2026 in Review
Bank of New York Mellon increased its Arcus Biosciences (RCUS) stake by 6.2% in Q2 2026, buying an estimated $787K and bringing the position to 543,009 shares worth $16.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1732.
Bank of New York Mellon first reported a position in RCUS in Q2 2018 and has held it in 33 quarters since. 77 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.
- Bank of New York Mellon held 543,009 shares of Arcus Biosciences worth $16.7M as of Q2 2026.
- Bank of New York Mellon bought 31,843 Arcus Biosciences shares in Q2 2026, an estimated $787K.
- Arcus Biosciences made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1732 holding.
- Bank of New York Mellon first reported a position in Arcus Biosciences in Q2 2018 and has held it in 33 quarters since.
- 77 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.